Drugs to be avoided in patients with long QT syndrome: Focus on the anaesthesiological management

Giovanni Fazio, Federica Vernuccio, Giuseppe Grutta, Giuseppe Lo Re

INTRODUCTION

Long QT syndrome (LQTS) is a cardiac conduction disorder characterized by prolongation and increased dispersion of ventricular repolarization, manifested by lengthening of the QT interval on the surface electrocardiography (ECG). This abnormal repolarization, when amplified by sympathetic activity, can lead to the formation of reentry circuits and may present with syncope, seizures, or torsades de pointes (TdP), ventricular fibrillation and, therefore sudden cardiac death[1]. Moreover, there are other signs of the torsadogenic property of a drug: QT dispersion (difference between the longest and the shortest QT interval) and the transmural dispersion of repolarization (TDR) (time between the peak and the end of the T wave in a precordial lead)[2]. Traditionally, LQTS is divided into congenital (c-LQTS) and acquired...
(a-LQTS) forms. Drug-induced LQTS is the most common cause of a-LQTS; as a matter of fact, a survey by Schwartz et al. of 670 patients in the International LQTS Registry revealed that anesthesia can trigger LQTS.

Ninety-five percent of drug-induced LQTS is due to the obstruction of the rapid component of the late correcting potassium current (I_{Kr}), which physiologically allows the rapid potassium outflow. I_{Kr} and the slow component of the same channel (I_{Ks}) are responsible for the repolarization of cardiomyocytes. Some anesthetics and some drugs used in premedication may lead to QT-prolongation. The available data on the prevention of lethal TdP during anesthesia in patients with c-LQTS is scant and conflicting; only case reports and small case series with different outcomes, even when using the same anesthetic agent, have been published. Although a-LQTS is of significant interest, this review focuses on the anesthetic recommendations for patients diagnosed with c-LQTS. Our aim is to provide some key points which could help both the cardiologists and the anesthetists when approaching a patient with LQTS candidate for anaesthesiological procedures. Firstly, we describe which drugs should be avoided in LQTS and then we move on the specific topic of the review describing the anaesthesiological management of patients with LQTS.

**DRUGS TO BE AVOIDED IN LQTS**

Certain drugs, including some anesthetics, are known to contribute to QT-prolongation. Considering that not all agents that prolong the QT interval increase TDR, drugs can be distinguished into the following groups depending on their simultaneous effects on the QT corrected using the Bazett’s formula (QTc) interval and on TDR: (1) drugs inducing both QTc prolongation and increased TDR, characterized by a high torsadogenic potential; (2) drugs causing QTc prolongation but with a slight effect on TDR and little, if any, ability to induce TdP; and (3) drugs causing both QTc prolongation and increased TDR below a certain concentration, but inducing TdP once a critical value of TDR is exceeded.

Drugs that prolong the QT interval and/or induce Torsades de Pointes in patients with diagnosed or suspected c-LQTS are shown on Table 1 and can be found on the web pages www.torsades.org. Some of these drugs are not available in every country (many of them have been withdrawn from the market in several countries). However, this list doesn’t include some anesthetic agents which have an influence on cardiac conduction and can lead to intraoperative TdP, hence, they are discussed throughout the text.

**ANAESTHETICS IN LQTS**

Despite an adequate β-blocking, patients with LQTS candidate to surgical or anesthetic procedure have an increased risk of developing perioperative ventricular arrhythmias. The probability of developing these arrhythmias significantly decreases with a careful pre-, intra- and post-operative management.

**Preoperative management**

A good anaesthesiological preoperative physical examination should be the cornerstone, mostly in childhood and adolescence. Moreover, an ECG at rest is always needed in order to reveal a QT prolongation. Patients treated with beta-blockers should continue their medication throughout the perioperative period until the operating day. Electrolytes should be normalized. Drugs known to induce TdP (Table 1) should be discontinued or the dose should be decreased if it cannot be discontinued. The presence of a pacemaker or implantable cardioverter defibrillator should be checked.

**Perioperative management**

Some anesthetics and some drugs used for premedication may lead to QT-prolongation. The torsadogenic effect is related both to the drug and to the anaesthesiological and surgical manoeuvres.

**Drugs used for premedication and sedation**

Since anxiety and pain can trigger arrhythmias in patients with LQTS, pre-anesthetic medication is recommended. Anesthetic premedication is usually performed using vagolytic and sedative/analgesic drugs. Among these drugs, atropine causes a lengthening of the QT interval and should not be used. On the other hand many studies demonstrated that midazolam does not modify either QT or TDR; hence, it should be used for premedication in patients with c-LQTS. Midazolam reduces sympathetic activity in unstimulated patients but it does not blunt the hemodynamic response to oral or nasal intubation. Few authors verified the utility of different drugs to prevent lengthening of QTc interval associated to intubation: Owczuk et al. demonstrated that the use of intravenous lidocaine (1.5 mg/kg) before laryngoscopy and intubation prevented prolongation of the QTc interval induced by the maneuver. Therefore, it seems useful the association of midazolam in premedication and lidocaine before intubation.

Droperidol, used for neuroleptanalgesia in intensive-care treatment since 1970, extends the QTc interval by the IKr current blockade through the HERG channel; because of this effect on QTc this drug was withdrawn from the market in 2001. This decision was focus of debate; hence, the drug was licensed again in 2008 and it is used in premedication both for sedation and antiemetic treatment. However, Staikou et al. advise against the use of droperidol in patients with LQTS in a recent review.

Lastly, an adequate sedoanalgesia reduces catecholamine release; the most used drugs are morphine, meperidin and fentanyl. Though the effects of fentanyl on QTc interval are conflicting, fentanyl and morphine have been used in patients with c-LQTS without any adverse effect. On the other hand, Song et al. recently re-
ported that the intravenous injection of meperidine led to QTc prolongation, polymorphic ventricular tachycardia and ventricular fibrillation, in a 16-year-old boy without neither underlying cardiac disease nor mutation in LQTS genes, but with a single nucleotide polymorphism, including H558R in SCN5A and K897T in KCNH2. Alfentanil does not extend repolarization time. On the contrary, sufentanil prolongs QTc interval\cite{38}.

### General anesthesia

**Induction and maintenance:** Induction of anesthesia can be done using halogenated volatile anesthetics or using intravenous agents, which are distinguished in barbiturates (sodium thiopental) and non barbiturates.
(Propofol or Ketamine). Maintenance of anesthesia is usually achieved by allowing the patient to breath a carefully controlled mixture of oxygen, nitrous oxide, and a volatile anaesthetic agent or by having a total intravenous anesthesia (TIVA) using intravenous agents in infusion together with analgesia.

Halogenated volatile anesthetics (Halothane, Enflurane, Isoflurane, Desflurane and Sevoflurane) prolong the QTc interval, even if data is controversial for some of them\textsuperscript{[39-43]}. Isoflurane has been used safely in patients with LQTS\textsuperscript{[13,44]}. Sevoflurane produced significant arrhythmias in a pediatric patient with c-LQTS\textsuperscript{[45]; moreover, it causes lengthening of QTc interval both in young and adults\textsuperscript{[45-49]}. The clinical significance of these findings in patients with LQTS is unclear\textsuperscript{[50]}, but it is recommended to avoid these agents.

Thiopental (sodium thiopental) has been used safely in patients with c-LQTS even if it causes QTc prolongation in humans\textsuperscript{[13,51-53]}. Thiopental may reduce TdP but it is recommended to avoid its use in patients with c-LQTS. Although Ketamine was used in premedication in children with undiagnosed c-LQTS, it is not recommended in patients with LQTS because its sympathomimetic properties can favor incidence of TdP\textsuperscript{[51]}. Etomidate does not affect the duration of ventricular repolarization\textsuperscript{[25,60]}. However, Erdil \textit{et al.}\textsuperscript{[61]} compared the effect of Propofol and Etomidate during electroconvulsive therapy, which may cause an acute rise in QT dispersion, and they found out that Etomidate increased QT more than Propofol.

\textbf{Anesthesiologic maneuvers}

\textbf{Intubation and extubation:} Usually the prophylactic administration of muscle relaxants eases intubation. Succinylcholine has been used in some patients with c-LQTS but it may either prolongs the QT interval in patients with c-LQTS, especially during tracheal intubation, or determine a vagal stimulation or result in asystole after pacemaker inhibition by fasciculations; for these reasons it should be avoided\textsuperscript{[19,22,62-64]}. The effects of succinylcholine on QTc can be reversed by alfentanil; the same is not possible with fentanyl\textsuperscript{[65]}. Moreover, alfentanil was better than esmolol in preventing the increase in QT\textsubscript{I} induced by succinylcholine during tracheal intubation\textsuperscript{[66]}. Rocuronium, vecuronium, atracurium, and cisatracurium do not extend the QTc interval and can be used in c-LQTS, while pancuronium should be avoided because of its vagolytic properties and because it caused ventricular fibrillation in a case report\textsuperscript{[14,23,35,1,32]}.

Both intubation and extubation may trigger a TdP in patients with c-LQTS: hence, additional care should be taken during these maneuvers and analgesic or beta-blockers should be administered before them. As aforementioned, the use of lidocaine before intubation proved to be safe to prevent arrhythmias\textsuperscript{[66]}. Finally, during ventilation with positive pressure, anesthesiologists should avoid high inspiratory pressure peaks and wide inspiratory/expiratory ratios, since the Valsalva maneuver also prolongs the QTc interval\textsuperscript{[66]}. Postoperative management

Postoperative management of patients with c-LQTS should include the permanence in a postsurgical intensive care unit for at least 24 h, avoiding stimuli that could trigger TdP. An adequate postoperative analgesia and beta-blocking must be guaranteed. Postoperative nausea and vomiting (PONV) prevention can not be performed with setrones (ondansetron, granisetron and dolasetron) in patients with c-LQTS because these drugs block not only the 5HT\textsubscript{3} receptors but also the HERG channel, determining a prolongation of repolarization. A study by Charbit \textit{et al.}\textsuperscript{[67]} demonstrated that 4 mg of ondansetron induced prolongation of the QTc, similar to the effect of 0.75 mg of droperidol, therefore questioning the greater safety of ondansetron when compared to droperidol in the treatment of PONV; Accordingly Staikou \textit{et al.}\textsuperscript{[68]} advise against its use in patients with c-LQTS.

\textbf{CONCLUSION}

The prevalence of Long QT syndrome is close to 1/3000-1/5000\textsuperscript{[69,70]}. The QT interval duration is physiologically variable: the QTc is calculated using the Bazzet’s formula [(QTc = QT/√RR), Table 2]\textsuperscript{[70,71]} Genetic testing can help to recognize specific subtypes of c-LQTS. The most common phenotypes are LQT1, LQT2 and LQT3. People with LQT1, the most common variant of LQTS, are more likely to have a cardiac event during exercise than patients with LQT2 or LQT3. LQT1 is associated with a mutation in the \textit{KCNQ1} gene (also known as KCNQ1), which codes for a protein that co-assembles with another protein (minK) to form the I\textsubscript{Ks} channel\textsuperscript{[71,72]}. In patients with LQT2 arrhythmic events are usually triggered by auditory stimuli or sudden startle\textsuperscript{[71]}. LQT2 is caused by the loss of I\textsubscript{KC} channel\textsuperscript{[71]}. Patients with LQT3 are prone to syncope or cardiac arrest at rest or during sleep; as a matter of fact, their electrocardiographic abnormalities become less marked at increased heart rate\textsuperscript{[72,74]}.

Table 2 Normal QT corrected using the Bazzet’s formula duration by age and gender

| QTc value (s) | Children (1-15 yr) | Male ( > 15 yr) | Female ( > 15 yr) |
|--------------|--------------------|-----------------|------------------|
| Normal       | < 0.44             | < 0.43          | < 0.45           |
| Borderline   | 0.44-0.46          | 0.43-0.45       | 0.45-0.46        |
| Prolonged    | > 0.46             | > 0.45          | > 0.46           |
3 shows the electrocardiographic patterns of the most common phenotypes of LQTS. Both in the a-LQTS and in the c-LQTS, the blockade of ionic channels, the lengthening of the QT interval and the intensification of QT interval can provoke the induction of TdP\(^8\). A careful pre-, peri- and post-operative management is needed for patients with this syndrome because of the risk of TdP and malignant arrhythmias. We speculate that genetic subtyping of patients with LQTS could help tailor anesthetic therapy for these high-risk patients.

Actually, there are no definitive guidelines for pre-, peri- and post-operative anesthetic management of c-LQTS. After reviewing the literature, we furnish some key points for preoperative optimization, intraoperative anesthetic agents and postoperative care plan that may be the best for patients with c-LQTS who undergo surgery. In the preoperative period it is necessary to calculate QTc, perform a 12-lead ECG at rest, discontinue or decrease the dose of drugs which could increase QTc interval and trigger a TdP in these patients (Table 1), continue beta-blocking therapy until the operating day and maintain calm and quiet environment. Defibrillator must be available for immediate use during the perioperative period.

In the perioperative period, it would be better to do premedication with midazolam, sedoanalgesia with morphine or fentanyl, induction and maintenance of anesthesia with thiopental or propofol TIVA avoiding halogenated volatile anesthetics and ketamine. Before intubation and extubation, the use of a topic anesthetic, an analgesic or a beta-blocker could be recommended. Among muscle relaxant drugs, we should prefer vecuronium and atracurium. It is important to monitor not only heart rate, blood pressure, oximetry, capnometry but also ECG in at least two leads, as short episodes of TdP are hardly distinguished from monomorphic VT, when traced in one lead. In the postoperative the patient must be monitored and ECG should last until patient emerges from anesthesia and QTc turns into preoperative values. Any kind of stimulus should be avoided since they could trigger TdP and pain must be adequately controlled.

**REFERENCES**

1 Schwartz PJ, Priori SG, Napolitano C. The long QT syndrome. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. 3rd ed. Philadelphia: WB Saunders, 2000: 597-615
2 Owczuk R, Wujtewicz MA, Zieniuck-Krajka A, Lasinski-Kowara M, Piankowski A, Wujtewicz M. The influence of anesthesia on cardiac repolarization. Minerva Anestesiol 2012; 78: 483-495 [PMID: 22318402]
3 Schwartz PJ, Priori SG, Spazolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheny P, Breithardt G, Keating MT, Towbin JA, Boggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattana-sirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89-95 [PMID: 11136691 DOI: 10.1161/101.CIR.103.1.89]
4 De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005; 26: 590-597 [PMID: 15637086 DOI: 10.1093/eurheartj/ehi092]
5 Tacken MC, Bracke FA, Van Zundert AA. Torresade de points during sevoflurane anesthesia and fluvonazolo infusion in a patient with long QT syndrome. A case report. Acta Anaesthesiol Belg 2011; 62: 105-108 [PMID: 21919379]
6 Mandal B, Kaur G, Batra YK, Mahajan S. Manifestation of Long QT syndrome with normal QTc interval under anesthesia: a case report. Paediatr Anaesth 2011; 21: 1265-1267 [PMID: 21824216 DOI: 10.1111/j.1460-9592.2011.03679.x]
7 Kim HT, Lee JH, Park IB, Heo HE, Kim TY, Lee MJ. Long QT syndrome provoked by induction of general anesthesia -A case report-. Korean J Anaesthesiol 2010; 59 Suppl: S114-S118 [PMID: 21286418 DOI: 10.4097/kjaneurol.2010.59.S.S114]
8 Komarlu R, Beerman L, Freeman D, Arora G. Fetal and neonatal presentation of long QT syndrome. Pacing Clin Electrophysiol 2012; 35: e67-e90 [PMID: 21401653 DOI: 10.1111/j.1460-9592.2011.05276.x]
9 Thiruvenkatarajan V, Osborn KD, Van Wijk RM, Euler P, Sethi R, Moodie S, Biradar V. Torresde de points in a patient with acute prolonged QT syndrome and poorly controlled diabetes during sevoflurane anaesthesia. Anaesth Intensive Care 2010; 38: 555-559 [PMID: 20514968]
10 Kenyon CA, Flick R, Moir C, Ackerman MJ, Pabelick CM. Anaesthesia for videoscopic left cardiac sympathetic denervation in children with congenital long QT syndrome and catecholaminergic polymorphic ventricular tachycardia— a case series. Paediatr Anaesth 2010; 20: 465-470 [PMID: 20357975 DOI: 10.1111/j.1460-9592.2010.03293.x]
11 Lin MT, Wu MH, Chang CC, Chiu SN, Thériault O, Huang H, Christé G, Ficker E, Chahine M. In utero onset of long QT syndrome with atrioventricular block and spontaneous or lidocaine-induced ventricular tachycardia: compound effects of hERG pore region mutation and SCN5A N-terminus variants. Heart Rhythm 2008; 5: 1567-1574 [PMID: 18840812 DOI: 10.1016/j.hrthm.2008.08.010]
12 Femenia F, Ruiz-Cimeno JL, Ferre MA, Cabezudo L, Vives C, Barberà M. [Total intravenous anesthesia for repositioning an implantable defibrillator in a patient with long QT syndrome]. Rev Esp Anestesiol Reanim 2008; 55: 367-370 [PMID: 18693663]
13 Johnston AJ, Hall JM, Levy DM. Anaesthesia with remifentanil and rocuronium for caesarean section in a patient with long-QT syndrome and an automatic implantable cardioverter-defibrillator. Anaesthesia 2000; 55: 133-136 [PMID: 15321099 DOI: 10.1016/j.anesthesia.1999.0362]
14 Al-Refaie A, Gunka V, Douglas J. Spinal anesthesia for Cesarean section in a parturient with long QT syndrome. Can J Anaesth 2004; 51: 993-996 [PMID: 15574549]
15 Pleym H, Baten J, Spigset O, Gisvold SE. Ventricular fibrillation related to reversal of the neuromuscular blockade in a patient with long QT syndrome. Acta Anaesthesiol Scand 1999; 43: 352-355 [PMID: 10801545 DOI: 10.1034/j.1399-6576.1999.00319.x]
16 Nair L, Tseng PS, Manninen PH, Teo WS. Anaesthetic management of idiopathic long QT syndrome—a case report. Ann Acad Med Singapore 1994; 23: 582-585 [PMID: 7979136]
Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. Heart Rhythm 2005; 2: 59-15 [PMID: 16253930 DOI: 10.1016/j.hrthm.2004.09.011]

http://www.azcert.org/medical-pros/drug-lists/CLQTS.cfm

Atlee JL, Kampine JP. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesthesiology 1991; 74: 137-144 [PMID: 1988684 DOI: 10.1016/0003-2999(91)90257-H]

Michaloudis D, Fraikasi O, Lefaki T, Dede I, Kanakoudes F, Askotopoulou H, Pollard B. Anaesthesia and the QT interval in humans. The effects of isoflurane and halothane. Anaesthesia 1996; 51: 219-224 [PMID: 8712519 DOI: 10.1111/j.1365-2044.1996.tb13636.x]

Owczuk R, Wujtewicz MA, Sawicka W, Lasek J, Wujtewicz M. The influence of desflurane, isoflurane, and halothane on the QT interval. Anesthesiology 2005; 101: 419-22, table of contents [PMID: 16037155 DOI: 10.1213/01.ANE.0000154198.41162.FA]

Karagöz AH, Basgil E, Celiker V, Ayapar U. The effect of inhalational anaesthetics on QTc interval. Eur J Anaesthesiol 2005; 22: 171-174 [PMID: 15852988 DOI: 10.1017/S026441560500030X]

Sausinne M, Massaad I, Raczká F, Davy JM, Frapier JM. Torsade de pointes during sevoflurane anaesthesia in a child with congenital long QT syndrome. Paediatr Anaesth 2006; 16: 63-65 [PMID: 16409532 DOI: 10.1111/j.1460-9592.2005.01593.x]

Paventi S, Santarevecchi A, Ranieri R. Effects of sevoflurane versus propofol on QT interval. Minerva Anestesiol 2001; 67: 657-640 [PMID: 11731753]

Nakao S, Hatano K, Sumi C, Masuzawa M, Sakamoto S, Ikeda S, Shingu K. Sevoflurane causes greater QTc interval prolongation in elderly patients than in younger patients. Anesth Analg 2010; 110: 775-779 [PMID: 2085656 DOI: 10.1213/ANE.0b013e3181cd6713]

Gürkan Y, Canatay H, Agacikken A, Ural E, Toker K. Effects of halothane and sevoflurane on QT dispersion in paediatric patients. Paediatr Anaesth 2003; 13: 223-227 [PMID: 12641684 DOI: 10.1046/j.1460-9592.2003.03141]

Kleinasser A, Kuenszberg E, Loockinger A, Keller C, Hoermann C, Lindner KH, Puehringer F. Sevoflurane, but not propofol, significantly prolongs the Q-T interval. Anesthesiology 2000; 90: 25-27 [PMID: 10624970 DOI: 10.1097/00000539-200001000-00006]

Loockinger A, Kleinasser A, Maier S, Furtner B, Keller C, Kuehneacher G, Linhardt KH. Sustained prolongation of the QTc interval after anesthesia with sevoflurane in infants during the first 6 months of life. Anesthesiology 2003; 98: 639-642 [PMID: 12606907 DOI: 10.1097/00000542-200308000-00011]

Scuderie PE. Sevoflurane and QTc Prolongation: An Interesting Observation, or a Clinically Significant Finding? Anaesthesiology 2010; 113: 772-775 [PMID: 20880285 DOI: 10.1097/ALN.0b013e3181zd088]

Kies SJ, Fabelick CM, Hurley HA, White RD, Ackerman MJ.
Anesthesia for patients with congenital long QT syndrome. *Anesthesiology* 2005; 102: 204-210 [PMID: 15618804 DOI: 10.1097/00000542-200501000-00029]

Drake E, Preston R, Douglas J. Brief review: anesthetic implications of long QT syndrome in pregnancy. *Can J Anaesth* 2007; 54: 561-572 [PMID: 17602043 DOI: 10.1007/BF03023231]

Wilton NC, Hantler CB. Congenital long QT syndrome: changes in QT interval during anesthesia with thiopental, vecuronium, fentanyl, and isoflurane. *Anesth Analg* 1987; 66: 357-360 [PMID: 2882709 DOI: 10.1213/00000539-19870400-0 0015]

McConachie J, Keaveny JP, Healy TE, Vohra S, Million L. Effect of anesthesia on the QT interval. *Br J Anaesth* 1989; 63: 558-560 [PMID: 2605703 DOI: 10.1093/bja/63.5.558]

Oji M, Terao Y, Toyoda T, Kuriyama T, Miura K, Fukusaki M, Sumikawa K. Differential effects of propofol and sevoflurane on QT interval during anesthetic induction. *J Clin Monit Comput* 2012; Epub ahead of print [PMID: 23242843]

Irie T, Kaneko Y, Nakajima T, Saito A, Kurabayashi M. QT interval prolongation and torsade de pointes induced by propofol and hypoaalbuminemia. *Int Heart J* 2010; 51: 365-366 [PMID: 20966611 DOI: 10.1536/ijh.51.365]

Higashijima U, Terao Y, Ichinomiya T, Miura K, Fukusaki M, Sumikawa K. A comparison of the effect on QT interval between thiamylal and propofol during anesthetic induction*. *Anesthesia* 2010; 65: 679-683 [PMID: 20528337 DOI: 10.1111/ j.1365-2044.2010.06341.x]

Hanci V, Aydin M, Yurtlu BS, Ayoğlu H, Okey RD, Taş E, Erdoğan G, Aydoğlan K, Turan IO. Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals. *Kardiol Torakog J* 2010; 26: 470-477 [PMID: 20837343 DOI: 10.1016/S1607-551X(10)70074-7]

Kleinsasser A, Loeckinger A, Lindner KH, Keller C, Boehler M, Puehringer M. Reversing sevoflurane-associated Q-Tc prolongation by changing to propofol. *Anesthesiology* 2001; 95: 248-250 [PMID: 11251432 DOI: 10.1097/00000542-200106000-00017]

Lischke V, Wilke HJ, Probst S, Behme N, Kessler P. Prolongation of the QT-interval during induction of anesthesia in patients with coronary artery disease. *Acta Anaesthesiol Scand* 1994; 38: 144-148 [PMID: 8171949 DOI: 10.1111/ j.1399-6576.1994.tb03856.x]

Erdil F, Demirbilek S, Begeç Z, Oztürk E, Ersoy MO. Effects of propofol or etomidate on QT interval during electroconvulsive therapy. *J ECT* 2009; 25: 174-177 [PMID: 19225403 DOI: 10.1097/YCT.0b013e3181930fa5]

Plötz J, Heidegger H, von Rubio G, Grohmann H, Deeg KH. [Hereditary prolonged QT interval (Romano-Ward syndrome) in a female patient with non-elective cesarean section]. *Anaesthesist* 1992; 41: 88-92 [PMID: 1562988]

Strickland RA, Stanton MS, Olsen KD. Prolonged QT syndrome: perioperative management. *Mayo Clin Proc* 1993; 68: 1016-1020 [PMID: 8412352 DOI: 10.1016/S0025-6196(12)62277-4]

Finser SR. Pacemaker failure on induction of anesthesia. *Br J Anaesth* 1991; 66: 509-512 [PMID: 2025841 DOI: 10.1093/bja/66.4.509]

Lorentz MN, Ramiro FG. [Anesthesia and the long QT syndrome.]. *Rev Bras Anestiol* 2007; 57: 543-548 [PMID: 19462131]

Korpinen R, Saarnivaara L, Siren K, Sarna S. Modification of the haemodynamic responses to induction of anaesthesia and tracheal intubation with alfentanil, esmolol and their combination. *Can J Anaesth* 1995; 42: 298-304 [PMID: 7788827 DOI: 10.1007/BF03010706]

Charbit B, Albaldadejo P, Fucnk-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. *Anesthesiology* 2005; 102: 1094-1100 [PMID: 15915019 DOI: 10.1097/00000542-200506000-00006]

Ackerman MJ. The long QT syndrome: ion channel diseases of the heart. *Mayo Clin Proc* 1998; 73: 250-269 [PMID: 9511785 DOI: 10.4065/73.3.250]

Crotti L, Spazzolini C, Schwartz PJ, Shimizu W, Denjoy I, Schulze-Bahr E, Zaklyazmiskaya EV, Swan H, Ackerman MJ, Moss AJ, Wilde AA, Horie M, Brink PA, Insolia R, De Ferrari GM, Crimi G. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. *Circulation* 2007; 116: 2366-2375 [PMID: 17984373 DOI: 10.1161/CIRCULATIONAHA.107.726950]

Garson A. How to measure the QT interval—what is normal? *Ann J Cardiol* 1993; 72: 14B-16B [PMID: 8256749 DOI: 10.1016/0003-4975(93)90034-A]

Moss AJ, Robinson J. Clinical features of the idiopathic long QT syndrome. *Circulation* 1992; 85: 1140-1144 [PMID: 1345816]

Levine E, Rosero SZ, Budzikowski AS, Moss AJ, Zareba W, Daubert JP. Congenital long QT syndrome: considerations for primary care physicians. *Cleve Clin J Med* 2008; 75: 591-600 [PMID: 18756841 DOI: 10.3949/ccjm.75.8.591]

Wilde AA, Jongbloed RJ, Doevendans PA, Dueren DR, Hauer RN, van Langen IM, van Tintelen JP, Smeets HJ, Meyer H, Geelen JL. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQIT1-related patients (LQTS1). *Am J Cardiol* 1999; 83: 327-332 [PMID: 9973011 DOI: 10.1016/S0735-1097(98)00578-6]

Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T, Suyama K, Aihara N, Sunagawa K, Echigo S, Miyamoto I, Schulze-Bahr E, Zaklyazminskaya EV, Swan H, Ackerman MJ, Moss AJ, Wilde AA, Horie M, Brink PA, Insolia R, De Ferrari GM, Crimi G. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. *Circulation* 2007; 116: 2366-2375 [PMID: 17984373 DOI: 10.1161/CIRCULATIONAHA.107.726950]

P-R Reviewer Panchal R S-Editor Huang XZ L-Editor A E-Editor Zhang DN